METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES

Abstract: Method for the detection of the antibiotic resistance spectrum of Mycobacterium species present in a sample, possibly coupled to the identification of the Micobacterium species involved, comprising the steps of: (i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (ii) if need be amplifying the relevant part of the antibiotic resistance genes present in said sample with at least one suitable primer pair; (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least one of the <u>rpo</u>B gene probes, as specified in table 2, under the appropriate hybridization and wash conditions; (iv) detecting the hybrids formed in step (iii); (v) inferring the Mycobacterium antibiotic resistance spectrum, and possibly the Mycobacterium species involved from the differential hybridization signal(s) obtained in step (iv).

Description: METHOD FOR THE DETECTION OF THE ANTIBIOTIC RESISTANCE SPECTRUM OF MYCOBACTERIUM SPECIES The present invention relates to the field ot drug-resistant mycobacteπa The present invention relates to probes, primers, methods and kits comprising tiic same tor the detection of mycobacteπal nucleic acids m biological samples. Identification of most clinically relevant Mycobacterium species, in particular of Mycobacterium tuberculosis is tedious and time consuming due to culture-procedures which can take up to 6 weeks. Rapid diagnosis of Mycobacterium i"' tion is very important since the disease might be life-threatening and highly contagious. O,.._v recently some methods - all making use ot one or another amplification process - have been developed to detect and identity Mycobacterium species without the need tor culture (Claπdge et al.. 1993). Most ot these methods are still in evaluation and their benefit in routine applications remains questionable. Moreover, these methods do not soh e the problem ot Mycobacterium drug- resistance detection which still relies on culture. Since the frequency of multidrug resistance in tuberculosis is steadily increasing (Culhton. 1992). it is clear now that early diagnosis ot M_ tuberculosis and the rapid recognition of resistance to the major tuberculostatics are essential tor therapy and an optimal control of the resurgent epidemic. The antibiotics used tor treatment of M__ tuberculosis infections are mainh isoniazid and πtampicm either administered separately or as a combination ot both. Occasionally, pyrazinamide. ethambutol and streptomycin are used: other classes ot antibiotics like (fluoro)quιnolones may become the preferred tuberculostatics in the future. Since most multidrug resistant mycobacteπa also lost susceptibility to πtampicin. πfampicin-resistance is considered to be a potential marker tor multidrug resistant tuberculosis. For this reason, the detection ot resistance to πtampicin might be ot particular relevance. For the majority of the jVL tuberculosis strains examined so tar. the mechanism responsible for resistance to πfampicin (and analogues like πfabutin) has been elucidated. Rifampicin (and analogues) block the RNA polymerase by interacting with the β-subunit ot this enzyme. Telenti et al. ( 1993a) found that mutations in a limited region ot the β-subumt of the RNA polymerase ot M tuberculosis gι\ e rise to insensitivity ot the RNA polymerase tor πfampicin action. This region is limited to a stretch of 23 codons in the rpoB gene. The authors describe 17 amino acid changes provoking resistance to πfampicin (Telenti et al.. 1993b). These amino acid changes are caused by point mutations or deletions at 15 nucleotides or 8 amino acid codons respectively scattered over a stretch of 67 nucleotides or 23 amino acid codons. Telenti et al. (1993a and b) described a PCR-SSCP method to screen for the relevant mutations responsible for πfampicin resistance (SSCP refers to single-strand conformation polymorphism). SSCP analysis can be performed either by using radio-activity or by using fluorescent markers. In the latter case sophisticated and expensive equipment (an automated DNA-sequencing apparatus) is needed. The SSCP approach described has also other limitations with respect to specificity and sensitivity which might impede its routine use. Specimen can only be adequatly analysed directly if a significant load ot bacteria (microscopy score : > 90 organisms/field) is observed microscopically and on crude DNA samples strand- separation artefacts may be observed which complicate the interpretation ot the results. Kapur et al. (1994) describe 23 distinct ιp_oB alleles associated with πfampicin resistance. In addition to the mutations described by Telenti et al. ( 1993a). some new mutant rpoB alleles are described. However, the most frequently occuπ g alleles remain the same as those described before. In M- leprae. the molecular basis for πfampiciπ resistance was described by Honore and Cole ( 1993). Here too. resistance stemmed from mutations in the rp_oB gene, which encodes the beta subunit ot RNA polymerase ot M. leprae. Only a limited number ot resistant M- leprae strains (9) were analysed, and in most of them (8/9) resistance was due to a mutation affecting the Ser-425 residue. Clinically important mycobacteπa other than M- tuberculosis and M. leprae often show an innate, be it variable, resistance to πfampicin. This is the case for ML avium and M . - intracellulare. human pathogens for which only limited treatment options are available. Guerrero et al. ( 1994) compared the rpoB-gene sequences of different M.- avium and M . - intracellulare isolates with that of M. tuberculosis. Differences are present at the nucleotide level but a full amino acid identity was found with πfampicm-sensitive ML tuberculosis. These findings suggest that another mechanism of resistance, possibly a permeability barrier, applies for M. avium and M- intracellulare. The specific detection of point mutations or small deletions can elegantly be approached using hybridization procedures such as the reverse hybridization assay. However, the complexity observed in the relevant part of the rgoB gene does not allow a straightforward probe development. As will be exemplified further, it was one ot the objects of the present invention to design a specific approach allowing the detection ot most if not all mutations found so far in a fast and convenient way without the need tor sophisticated equipment. The mechanism of resistance to isoniazid (INH) is considerably more complex than that for πfampicin. At least two gene products are involved in INH-resistance. First, there is catalase-peroxidase which is believed to convert INH to an activated molecule. Hence, strains which do not produce catalase-peroxidase by virtue ot a detective or deleted katG gene are not anymore susceptible to INH (Zhang et al.. 1992: Stoeckle et al.. 1993). In this context it should be mentioned that the association between INH-resistance and the loss ot catalase activity was already noted in the fifties (Middlebrook. 1954 a and b; Youatt. 1969). The second molecule involved is the inhA gene product, w hich is believed to play a role in the mycolic acid biosynthesis. It is postulated that the activated INH molecule interacts either directly or indirectly with this product and probably prevents proper mycolic acid biosynthesis. This hypothesis is based on the recent observation that overexpression of the wild type mhA gene or a particular amino acid change (S94A) in the hA gene product confers resistance to INH (Banerjee et al., 1994). In short, and somewhat simplified we can state that in certain fv tuberculosis strains resistance to INH might be mediated by : the loss of catalase-peroxidase activity the presence of certain amino acid changes in the jnhA protein the expression level of the wild type inhA protein Also, other mechanisms might be involved in confeπng resistance to INH and related drugs. The importance of these factors in the total spectrum ot INH-resistance mechanisms has yet to be assessed. This issue can be addressed by means of DNA probe techniques if reliable DNA probes can be developed from the available DNA-sequences ot the katG gene (EMBL n° X68081) and inhA gene (EMBL n c U02492) of M. tuberculosis. These probe- tests could then also be applied for detection of drug resistance in biological samples. For the detection of resistance to streptomycine and (fluoro)quιnolones the same approach as for πfampicin can be followed. Resistance to these antibiotics is also induced by point mutations in a limited region of one or more genes Point mutations in the gyrase gene confer resistance to (fluoro)qumolones (EMBL ir L27512). Streptomycin resistance is correlated with mutations in either the 16S rRNA gene or the gene ot a πbosomal protein S 12 (rpsL) (Finken et al.. 1993: Douglas and Steyn. 1993: Nair et al.. 1993). Resistance due to nucleotide changes in the katG, rp_oB and rp_sL genes have been described in international application WO 93/22454. For each ot the different genes in M. tuberculosis only one of the many possible mutations was specified m detail, nl. R461 L for katG. S425L (equivalent to S531L described by Telenti et al. and the present invention) for rpoB and K42R for rpsL. It is an object of the present invention to provide a rapid and reliable detection approach for determination ot antibiotic resistance ot mycobacterial species present in a biological sample. More particularly, it is an aim ot the present invention to provide a rapid and reliable method for determination of resistance to πtampicin (and/or πtabutin) of M__ tuberculosis present in a biological sample. It is also an object of the present invention to provide methods enabling the detection and identification of Mycobacterium species in a biological sample, directly coupled to the monitoring of the antibiotic resistance spectrum. It is more particularly an aim of the present invention to provide a method to detect the presence of Mycobacterium tuberculosis in a biological sample directly coupled to the detection of πfampicin (and/or πtabutin) resistance. It is more particularly an aim of the present invention to provide a method to detect the presence of Mycobacterium leprae in a biological sample directly coupled to the detection of πfampicin (and/or πfabutin) resistance. It is also an aim of the present invention to select particular probes able to discriminate wild-type sequences from mutated sequences conferring resistance to one or more drugs. It is more particularly an aim ot the present invention to select particular probes able to discriminate wild-type sequences from mutated sequences conferring resistance to πfampicin (and/or πtabutin). It is more particularly an aim of the present invention to select a particular set of probes, able to discriminate wild-type sequences from mutated sequences conferring resistance to rifampicin (an/or rifabutin) with this particular set ot probes being used under the same hybridisation and wash-conditions. It is moreover an aim of the present invention to combine a set ot selected probes able to discriminate wild-type sequences from mutated sequences conferring resistance to rifampicin (and/or rifabutin) with another set ot selected probes able to identify the mycobacteπa species present in the biological sample, whereby all probes can be used under the same hybridisation and wash-conditions. It is also an aim of the present invention to select pππ.v s enabling the amplification of the gene fragment(s) determining the antibiotic resistance trait ot interest. It is more particularly an aim ot the present invention to select primers enabling the amplification of the rrioB-gene fragment determining resistance to rifampicin (and analogues) Another aim ot the invention is to provide kits tor the detection ot antibiotic resistance in mycobacteπa. possibly coupled to the identification ot the mycobacterial species involved. All the aims ot the present invention ha\ e been met by the following specific embodiments. The selection of the preferred probes ot the present invention is based on the Line Probe Assay (LiPA) principle which is a reverse hybridization assay using oligonucleotide probes immobilized as parallel lines on a solid support strip (Stuyver et al. 1993; inter nation,-., application WO 94/12670). This approach is particularly adv antageous since it is fast and simple to perform. The reverse hybridization format and more particularly the LiPA approach has many practical advantages as compared to other DNA techniques or hybridization formats, especially when the use ot a combination ot probes is preferable or unavoidable to obtain the relevant information sought. It is to be understood, however, that any other type of hybridization assay or format using any of the selected probes as described further in the invention is also covered by the present invention. The reverse hybridization approach implies that the probes are immobilized to a solid support and that the target DNA is labelled in order to enable the detection ot the hybrids formed. The following definitions serve to illustrate the terms and expressions used in the present invention. The target material in these samples may either be DNA or RNA e.g genomic DNA or messenger RNA or amplified versions thereof. These molecules are also termed polynucleic acids. The term "probe" refers to single stranded sequence-specific oligonucleotides which have a sequence which is complementary to the target sequence to be detected. The term complementary as used herein means that the sequence of the single stranded probe is exactly complementary to the sequence of the single-stranded target, with the target being defined as the sequence where the mutation to be detected is located. Since the current application requires the detection of single basepair mismatches, very stringent conditions for hybridization are required, allowing in principle only hybridization of exactly complementary sequences However, variations are possible the length of the probes (see below ), and it should be noted that, since the central part ot the probe is essential for its hybridization characteristics possible deviations ot the probe sequence versus the target sequence may be allowable towards head and tail of the probe, when longer probe sequences are used. These variations, which may be conceived from the common knowledge in the art, should however always be evaluated experimentally, in order to check if they result in equivalent hybridization characteristics than the exactly complementary probes. Preferably, the probes are about 5 to 50 nucleotides long, more preferably from about 10 to 25 nucleotides. The nucleotides as used in the present invention may be πbonucleotides. deoxyπbonucleotides and modified nucleotides such as inosine or nucleotides containing modified groups which do not essentially alter their hybridisation characteristics. Probe sequences are represented throughout the specification as single stranded DNA oligonucleotides from the 5' to the 3 ' end. It is obvious to the man skilled in the art that any of the below-specified probes can be used as such, or in their complementary form, or in their RNA form (wherein T is replaced by U). The probes according to the invention can be prepared by cloning of recombinant plasmids containing inserts including the corresponding nucleotide sequences, if need be by cleaving the latter out from the cloned plasmids upon using the adequate nucleases and recovering them, e.g. by fractionation according to molecular weight. The probes according to the present invention can also be synthesized chemically, for instance by the conventional phospho-tπester method. The term "solid support" can refer to any substrate to which an ohgonucleotide probe can be coupled, provided that it retains its hybridization characteristics and provided that the background level of hybridization remains low Usually the solid substrate will be a microtiter plate, a membrane (e.g. nylon or nitrocellulose) or a microsphere (bead). Prior to application to the membrane or fixation it may be convenient to modify the nucleic acid probe in order to facilitate fixation or improve the hybridization efficiency. Such modifications may encompass homopolymer tailing, coupling with different reactive groups such as aliphatic groups, NH : groups. SH groups, carboxylic groups, or coupling with biotin, haptens or proteins. The term "labelled" refers to the use ot labelled nucleic acids. Labelling may be carried out by the use of labelled nucleotides incorporated during the polymerase step of the amplification such as illustrated by Saiki et al. ( 1988) or Bei et al. ( 1990) or labelled primers, or by any other method known to the person skilled in the art The nature of the label may be isotopic ( 3 -P 5 S. etc.) or non-isotopic (biotin. digoxigenin. etc.). The term "primer ^ fers to a single stranded ohgonucleotide sequence capable ot acting as a point ot initiation tor synthesis ot a primer extension product which is complementary to the nucleic acid strand to be copied. The length and the sequence of the primer must be such that they allow to prime the synthesis ot the extension products. Preferably the primer is about 5-50 nucleotides long. Specific length and sequence will depend on the complexity of the required DNA or RNA targets, as well as on the conditions of primer use such as temperature and ionic strenght. The tact that amplification primers do not have to match exactly with the corresponding template sequence to warrant proper amplification is amply documented in the literature (Kwok et al. , 1990). The amplification method used can be either polymerase chain reaction (PCR; Saiki et al.. 1988). ligase chain reaction (LCR: Landgren et al. , 1988: Wu & Wallace, 1989: Barany. 1991), nucleic acid sequence-based amplification (NASBA; Guatelh et al. , 1990: Compton, 1991). transcription-based amplification system (TAS: Kwoh et al. , 1989), strand displacement amplification (SD Duck. 1990: Walker et al. , 1992) or amplification by means of Qβ rep case (Lizardi t al.. 1988: Lomeli et al. , 1989) or any other suitable method to amplify nucleic acid molecules known in the art. The oligonucleotides used as primers or probes may also comprise nucleotide analogues such as phosphorothiates (Matsukura et al. , 1987), alkylphosphorothiates (Miller et al.. 1979) or peptide nucleic acids (Nielsen et al.. 1991 ; Nielsen et al. , 1993) or may contain intercalating agents (Asse ne et al.. 1984). As most other variations or modifications introduced into the original DNA sequences of the invention these variations will necessitate adaptions with respect to the conditions under which the ohgonucleotide should be used to obtain the required specificity and sensitivity. However the eventual results of hybridisation will be essentially the same as those obtained with the unmodified oligonucleotides. The introduction of these modifications may be advantageous in order to positively influence characteristics such as hybridization kinetics, reversibility ot the hybrid-formation, biological stability of the ohgonucleotide molecules, etc. The "sample" may be any biological material taken either directly from the infected human being (or animal), or after cultuπng (enrichment). Biological material mav be e.g. expectorations ot any kind, broncheolavages, blood, skin tissue, biopsies, lymphocyte blood culture material, colonies, liquid cultures, soil, faecal samples, urine etc. The probes ot the invention are designed tor attaining optimal performance under the same hybridization conditions so that they can be used in sets for simultaneous hybridization; this highly increases the usefulness of these probes and results in a significant gam in time and labour. Evidently, when other hybridization conditions would be preferred, all probes should be adapted accordingly by adding or deleting a number ot nucleotides at their extremities. It should be understood that these concommitant adaptations should give rise to essentially the same result, namely that the respective probes still hybridize specifically with the defined target. Such adaptations might also be necessary if the amplified material should be RNA in nature and not DNA as in the case for the NASBA system. For designing probes with desired characteristics, the following useful guidelines know n to the person skilled in the art can be applied. Because the extent and specificity of hybridization reactions such as those described herein are affected by a number of factors, manipulation ot one or more of those factors will determine the exact sensitivity and specificity of a particular probe, w hether perfectly complementary to its target or not. The importance and effect ot various assay conditions, explained further herein, are known to those skilled in the art. First, the stability of the [probe : target] nucleic acid hybrid should be chosen to be compatible with the assay conditions. This may be accomplished by avoiding long AT-πch sequences, by terminating the hybrids with G:C base pairs, and by designing the probe with an appropriate Tm. The beginning and end points ot the probe should be chosen so that the length and %GC result in a Tm about 2-10°C higher than the temperature at which the final assay will be performed. The base composition ot the probe is significant because G-C base pairs exhibit greater thermal stability as compared to A-T base pairs due to additional hydrogen bonding. Thus, hybridization involving complementary nucleic acids ot higher G-C content will be stable at higher temperatures. Conditions such as ionic strenght and incubation temperature under which a probe will be used should also be taken into account when designing a probe. It is known that hybridization will increase as the ionic strenght ot the reaction mixture increases, and that the thermal stability of the hybrids will increase with increasing ionic strenght. On the other hand, chemical reagents, such as tormamide. urea. DMSO and alcohols, which disrupt hydrogen bonds, will increase the stringency ot hybridization. Destabilization ot the hydrogen bonds by such reagents can greatly reduce the Tm In general, optimal hybridization for synthetic ohgonucleotide probes ot about 10-50 bases in length occurs approximately 5°C below the melting temperature for a given duplex Incubation at temperatures below the optimum may allow mismatched base sequences to hybridize and can therefore result in reduced specificity. It is desirable to have probes which hybridize only under conditions of high stringency. Under high stringency conditions only highly complementary nucleic acid hybrids will form: hybrids without a sufficient degree ot complementarity will not form. Accordingly, the stringency ot the assay conditions determines the amount of complementarity needed between two nucleic acid strands forming a hybrid The degree of stringency is chosen such as to maximize the difference in stability between the hybrid formed with the target and the nontarget nucleic acid. In the present case, single base pair changes need to be detected, which requires conditions ot very high stringency. Second, probes should be positioned so as to minimize the stability ot the [probe : nontarget] nucleic acid hybrid. This may be accomplished by minimizing the length of perfect complementarity to non-target organisms, by avoiding GC-πch regions ot homology to non- target sequences, and by positioning the probe to span as many destabilizing mismatches as possible. Whether a probe sequence is useful to detect only a specific type of organism depends largely on the thermal stability difference between [probe: target] hybrids and [probe: nontarget] hybrids. In designing probes, the differences in these Tm values should be as large as possible (e.g. at least 2°C and preferably 5°C). The length of the target nucleic acid sequence and. accordingly, the length of the probe sequence can also be important. In some cases, there may be several sequences from a particular region, varying in location and length, which will yield probes with the desired hybridization characteristics. In other cases, one sequence may be significantly better than another which differs merely by a single base. While it is possible tor nucleic acids that are not perfectly complementary to hybridize, the longest stretch ot perfectly complementary base sequence will normally primarily determine hybrid stability. While ohgonucleotide probes of different lengths and base composition may be used, preferred ohgonucleotide probes of this invention are between about 5 to 50 (more particularely 10-25) bases in length and have a sufficient stretch in the sequence which is perfectly complementary to the target nucleic acid sequence Third, regions in the target DNA or RNA which are known to form strong internal structures inhibitory to hybridization are less preferred Likewise, probes with extensive self- complementarity should be avoided. As explained above, hybridization is the association of two single strands ot complementary nucleic acids to form a hydrogen bonded double strand. It is implicit that it one of the two strands is wholly or partially involved in a hybrid that it will be less able to participate in formation of a new hybrid. There can be intramolecular and intermolecular hybrids formed within the molecules of one type ot probe it there is sufficient self complementarity . Such structures can be av oided through careful probe design. By designing a probe so that a substantial portion ot the sequence ot interest is single stranded. the rate and extent of hybridization may be greatly increased. Computer programs are available to search tor this type of interaction. However, in certain instances, it may not be possible to avoid this type of interaction. The present invention provides in its most general form tor a method to detect the antibiotic resistance spectrum of Mycobacterium species present in a sample, possibly coupled to the identification ot the Mycobacterium species involved, comprising the steps of: (0 if need be releasing, isolating or concentrating the polynucleic acids present in the sample: (n) if need be amplifying the relevant part of the antibiotic resistance genes present in said sample with at least one suitable primer pair; (in) hybridizing the polynucleic acids ot step (0 or (n) with at least one of the rpoB gene probes as mentioned in table 2, under appropiate hybridization and wash conditions: (iv) detecting the hybrids formed in step (in): (v) inferring the Mycobacterium antibiotic resistance spectrum, and possibly the Mycobacterium species involved from the differential hybridization sιgnal(s) obtained The relevant part of the antibiotic resistance genes refers to the regions in the rpoB. katG. inhA, 16S rRNA, rpsL and gyrase genes harboring mutations causing resistance to rifampicin, isoniazid, streptomycin and (fluoro)quιnolones as described above. According to a preferred embodiment of the present invention, step (in) is performed using a set of probes meticulously designed as such that they show the desired hybridization results, when used under the same hybridization and wash conditions. More specifically, the present invention provides a method tor detection ot rifampicin (and/or rifabutin) resistance of M- tuberculosis present in a biological sample, comprising the steps of : ( I) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (n) if need be amplifying the relevant part of the rpoB gene present in said polynucleic acids with at least one suitable primer pair: (in) hybridizing the polynucleic acids of step (l) or (n) with a selected set ot r joB wild- type probes under appropiate hybridization and wash conditions, with said set comprising at least one of the following probes (see Table 2) : S555 (SEQ ID NO 39) S5555 (SEQ ID NO 40) S55C (SEQ ID NO 44) S55M (SEQ ID NO 45) S6 (SEQ ID NO 1 1 ) S66 (SEQ ID NO 12) (iv) detecting the hybrids formed in step (in): (v) inferring the rifampicin susceptibility (sensitivity versus resistance) of M. tuberculosis present in the sample from the differential hybridization sιgnal(s) obtained in step (iv). The term ' susceptibility ' refers to the phenotypic characteristic ot the M . tuberculosis strain being either resistant or sensitive to the drug, as determined by in \ nro culture methods, more specifically to rifampicin (and/or rifabutin). Resistance to rifampicin is revealed by the absence of hybridization with at least one ot the S-probes. Standard hybridization and wash conditions are tor instance 3X SSC (Sodium Saline Citrate). 20% deionized FA (Formamide) at 50 C C. Other solutions (SSPE (Sodium saline phosphate EDTA). TMAC1 (Tetramethyl ammonium Chloride), etc.) and temperatures can also be used provided that the specificity and sensitivity of the probes is maintained. If need be. slight modifications of the probes in length or sequence have to be carried out to maintain the specificity and sensitivity required under the given circumstances Using the probes ot the invention, changing the conditions to 1.4X SSC. 0.07% SDS at 62 °C lead to the same hybridisation results as those obtained under standard conditions, w ithout the necessity to adapt the sequence or length of the probes. Suitable primer pairs can be chosen from a list of primer pairs as described below. In a more preferential embodiment, the above-mentioned polynucleic acids from step (l) or ( n) are hybridized with at least two. three, tour, e. six. seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen or seventeen ot the above-mentioned S- probes. preferably with 5 or 6 S-probes, which, taken together, cover the "mutation region" of the rpoB gene. The term "mutation region" means the region in the rpoB-gene sequence here most, if not all of the mutations responsible for rifampicin resistance are located. This mutation region is represented in tig. 1. In a more preferential embodiment, the above-mentioned polynucleic acids from step (i) or (ii) are hybridized with a selected set of rrjoB-wild-type probes, with said set comprising at least one, and preferentially all of the following probes (see Table 2) : Sl l (SEQ ID NO 2) S2 (SEQ ID NO 3) S33 (SEQ ID NO 5) S4444 (SEQ ID NO 8) S55 or S5555 (SEQ ID NO 10 or 40) In another particular embodiment the set of S-probes as described above, or at least one of them, can be combined with one or more SIL-probes. detecting silent mutations in the rpoB gene. A preferential SIL-probe is SIL-1 (SEQ ID NO 13. see Table 2). In another embodiment of the invention, the set of S-probes and possibly SIL-probes. can be combined with at least one R-probe detecting a specific mutation associated with rifampicin-res .stance. g group of probes (see Table 2) : R5C (SEQ ID NO 54) Preferably the set of S-probes and possibly SIL-probes can be combined with at least two. three, four, five. six. or more R probes. Most preferably, the set of S-probes and possibly SIL-probes are combined with at least one R-probe from the following restricted group of probes : R2 (SEQ ID NO 14) R444A (SEQ ID NO 17) R444B (SEQ ID NO 20) R55 (SEQ ID NO 22) In the case where S and R probes are combined, resistance to rifampicin is revealed by absence of hybridization with one ot the S-probes and possibly by a positive hybridization signal with the corresponding R-probe. Since some mutations may be more frequently occurring than others, e.g. in certain geographic areas (see e.g. Table 5) or in specific circumstances (e.g. rather closed communities) it may be appropiate to screen only for specific mutations, using a selected set of S and/or R probes. This would result in a more simple test, which would cover the needs under certain circumstances. According to Telenti et al. ( 1993a and b) most mutations described in his publication are relatively rare (3 % or less): predominant mutations are S531 L (51.6%). H526Y ( 12.5 %), D516V (9.4%) and H526D (7.8 %). In a particular embodiment of the invention a selected set ot two or three S-probes is used, the respective sets of probes being: S4444 (SEQ ID NO 8) S55 (or S5555) (SEQ ID NO 10 or 40) or S2 (SEQ ID NO 3) S4444 (SEQ ID NO 8) S55 (or S5555) (SEQ ID NO 10 or 40) Using this restricted sets of S-probes the majority ot rifampicin resistant cases can be detected, by an absence ot hybridisation signal with at least one ot these probes. In another particular embodiment of the invention, at least one R probe is used, possibly combined with a selected set of two or three S probes as described above, said R probe being chosen from the following list of probes: R2 (SEQ ID NO 14) R444A (SEQ ID NO 17) R444B (SEQ ID NO 20) R55 (SEQ ID NO 22) In this case, the specific mutation responsible tor the πtampicin-resistant phenotype can be inferred from a positive hybridization signal with one ot the R-probes and/or the absence of hybridization with the corresponding S-probe. In another embodiment of the invention, the above-mentioned S. SIL or R probes may be combined with at least one species-specific probe tor JVL tuberculosis allowing simultaneous identification of Mycobacterium tuberculosis and detection of rifampicin resistance, with said species-specific probe being chosen from the following group ot probes (see Table 2) : MT-POL- l (SEQ ID NO 23) MT-POL-2 (SEQ ID NO 24) MT-POL-3 (SEQ ID NO 25) MT-POL-4 (SEQ ID NO 26) MT-POL-5 (SEQ ID NO 27) Most preferably the species-specific JVL tuberculosis probe is: MT-POL-l (SEQ ID NO 23) In yet another embodiment of the invention, the above-mentioned S. SIL. R or MT- POL probes can be combined with at least one species-specific probe tor JVL paratuberculosis. JyL avium, M. scrophulaceum. JVL kansasu, JVL intracellulare (and MAC- strains) or M. leprae. with said probes being respectively MP-POL- 1 (SEQ ID NO 28), MA- POL- 1 (SEQ ID NO 29), MS-POL-1 (SEQ ID NO 38), MK-POL- 1 (SEQ ID NO 55), MI- POL-1 (SEQ ID NO 68) and ML-POL-1 (SEQ ID NO 57) (see table 2B) or any species- specific probe derived from the sequence of the relevant part of the rpoB gene of JVL paratuberculosis (SEQ ID NO 35), ML avium (SEQ ID NO 36). M- scrotulaceum (SEQ ID NO 37), M. kansasϊi (SEQ ID NO 56) or MAC-strains (SEQ ID NO 69), as represented respectively in figs. 5. 6, 7, 8 and 11. It should be noted that the sequences represented in figs. 5-8 and 1 1 are new. The sequence of the rjjoB-gene fragment of JVL intracellulare and JVL leprae has been described by others (Guerrero et al. 1994: Honore and Cole. 1993). The term "MAC-strains" means "M. avium complex" strains known to the man skilled in the art of mycobacteπa taxonomy. This rather heterogeneous group of MAC- strains may however comprise strains which are genotypically rather like M. intracellulare. This is also the case for isolate ITG 926, of which the rpoB sequence is shown in fig. 1 1. The MI-POL- 1 probe derived from SEQ ID NO 69 and the published M- intracellulare rpoB sequence is therefor specific for J L intracellulare and some MAC strains together. It should be stressed that all of the above-mentioned probes, including the species- specific probes, are contained in the sequence of the rp_oB gene, and more particulary in the sequence of the amplified ipoB gene fragment. Moreover, as illustrated further in the examples, the probes described above as "preferential" , are designed in such a way that they can all be used simultaneously, under the same hybridization and wash conditions. These two criteria imply that a single amplification and hybridization step is sufficient tor the simultaneous detection ot rifampicin resistance and the identification ot the mycobacterial species involved. In a preferential embodiment, and by way of an example, a method is disclosed to detect JvL tuberculosis and its resistance to rifampicin. comprising the steps of: (l) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (π) if need be amplifying the relevant part of the rpoB gene w ith at least one suitable primer pair; (in) hybridizing the polynucleic acids of step (l) or (n) with the follow ing set ot probes under appropriate hybridization and wash conditions MT-POL-l S l l S2 S33 S4444 S55 or S5555 R2 R444A R444B R55 ) detecting the hybrids formed in step (in): (v) inferring the presence ot M . - tuberculosis and its susceptibility to πfampicin from the differential hybridization sιgnal(s) obtained in step (iv). In order to detect the mycobacterial organisms and/or their resistance pattern with the selected set of ohgonucleotide probes, any hybridization method known in the art can be used (conventional dot-blot. Southern blot, sandwich, etc.). However, in order to obtain fast and easy results if a multitude ot probes are involved, a reverse hybridization format may be most convenient. In a preferred embodiment the selected set of probes are immobilized to a solid support. In another preferred embodiment the selected set ot probes are immobilized to a membrane strip in a line fashion. Said probes may be immobilized individually or as mixtures to delineated locations on the solid support. A specific and very user-friendly embodiment ot the above-mentioned preferential method is the LiPA method, where the above-mentioned set ot probes is immobilized in parallel lines on a membrane, as further described the examples. The above mentioned R-probes detect mutations which have already been described in the prior art (Telenti et al. , 1993a and 1993b). However, as illustrated further in the examples, four new mutations associated with rifampicm-resistance in M. tuberculosis, not yet described by others, are disclosed by the current invention Using the S-probes of the current invention, new mutations as well as mutations already described in the prior art can be detected. The unique concept of using a set ot S-probes covering the complete mutation region in the rpoB gene, allows to detect most, it not all ot the mutations in the rpoB-gene responsible for rifampicin resistance, even those mutations which would not yet have been described uptil now. The four new rpoB mutations (D516G, H526C, H526T and R529Q) are marked in Table 1 with an asterisk. By way of an example, the sequence of the rpoB- utant allele H526C is represented in Fig. 2 (SEQ ID NO 34). The invention also provides for any probes or pπmersets designed to specifically detect or amplify specifically these new rpoB gene mutations, and any method or kits using said pπmersets or probes. In another embodiment, the invention also provides for a method for detection of rifampicin (and/or rifabutin) resistance of M . - leprae present in a biological sample, comprising the steps of: (1) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (n) if need be amplifying the relevant part of the rpoB gene with at least one suitable primer pair; (in) hybridizing the polynucleic acids of step (0 or (n) with a selected set ot rpoB wild- type probes under appropiate hybridization and wash conditions, with said set comprising at least one of the following probes (see Table 2) : ML-S 1 (SEQ ID NO 58) ML-S2 (SEQ ID NO 59) ML-S3 (SEQ ID NO 60) ML-S4 (SEQ ID NO 61 ) ML-S5 (SEQ ID NO 62) ML-S6 (SEQ ID NO 63) (iv) detecting the hybrids formed in step (in); (v) inferring the rifampicin susceptibility (sensitivity versus resistance) of JVL leprae present in the sample from the differential hybridization sιgnal(s) obtained in step Resistance to rifampicin is revealed by the absence ot hybridization with at least one of the ML-S-probes. In another embodiment of the invention, the above-mentioned ML-S probes may be combined with a species specific probe for JVL leprae. ML-POL- 1. allowing simultaneous identification of VL leprae and detection of rifampicin resistance, with said species specific probe being represented in SEQ ID NO 57. It is to be noted that the above-mentioned ML-S probes and ML-POL- 1 probe are all contained within the same amplified rpoB-gene fragment ot L leprae. and are designed as such that they can all be used under the same hybridization and wash conditions. The invention further provides for any of the probes as described above, as wemm as compositions comprising at least one of these probes. The invention also provides for a set of primers, allowing amplification of the mutation region of the rn_oB gene of JVL tuberculosis. The sets ot primers can be chosen from the following group ot sets (see table 2): PI and P5 (SEQ ID NO 30 and 33) P3 and P4 (SEQ ID NO 31 and 32) P7 and P8 (SEQ ID NO 41 and 42) P2 and P6, in combination with (PI and P5) or (P3 and P4) or (P7 and P8) Most preferably, the set of primers is the following: P3 and P4 (SEQ ID NO 31 and 32). The invention also provides for a set of primers allowing amplification of the mutation region of the rpoB gene in mycobacteria in general, i.e. in at least JVL tuberculosis. JVL avium. JVL paratuberculosis. M- intracellulare, M. leprae, M. scrotulaceum. These general primers can be used e.g. in samples where the presence ot mycobacteria other than M. tuberculosis is suspected, and where it is desirable to have a more general detection method. The set of primers is composed of a 5 ' -pπmer. selected from the following set: MGRPO- 1 (SEQ ID NO 64) MGRPO-2 (SEQ ID NO 65) and a 3 ' -primer, selected from the following set: MGRPO-3 (SEQ ID NO 66) MGRPO-4 (SEQ ID NO 67). The sequence of these primers is shown in Table 2B. Primers may be labeled with a label of choice (e.g. biotine). Different primer-based target amplification systems may be used, and preferably PCR-amplification. as set out in the examples. Single-round or nested PCR may be used. The invention also provides for a kit for interring the antibiotic resistance spectrum ot mycobacteria present in a biological sample, possibly coupled to the identification of the mycobacterial species involved, comprising the following components: (0 when appropiate. a means for releasing, isolating or concentrating the polynucleic acids present in the sample; (n) when appropriate, at least one of the above-defined set of primers: (in) at least one of the probes as defined above, possibly fixed to a solid support: (iv) a hybridization buffer, or components necessary for producing said buffer: (v) a wash solution, or components necessary for producing said solution; (vi) when appropriate, a means for detecting the hybrids resulting from the preceding hybridization. The term "hybridization buffer" means a buffer enabling a hybridization reaction to occur between the probes and the polynucleic acids present in the sample, or the amplified products, under the appropiate stringency conditions. The term "wash solution" means a solution enabling washing of the hybrids formed under the appropiate stringency conditions. More specifically, the invention provides for a kit as described above, for the simultaneous detection of M. tuberculosis and its resistance to rifampicin. In another specific case, the invention provides for a kit as described above, for the simultaneous detection of M- leprae and its resistance to rifampicin. TABLE LEGENDS Table 1 summarizes the nucleotide and amino acid changes (described by Telenti et al. (1993a and b), Kapur et al. 1994 and the present invention) in the rpoB gene fragment of rifampicin resistant JVL tuberculosis isolates. Codon numbering is as in Fig. 1 . New mutations described by the current invention are indicated with an asterisk (~). Table 2 lists the sequences of the primers and probes selected from the rpoB gene. 2A: JVL tuberculosis 2B: other mycobacterial species Table 3 shows the hybridization results obtained with probe MT-POL- l . with DNA from different mycobacterial and non-mycobacteπal species. Table 4 shows some representative results obtained with LiPA tor some JVL tuberculosis isolates which have been sequenced and the interpretation ot the different LiPA patterns. Table 5 shows the occurrence ot the different rrjoB mutations in M. tuberculosis in different geographical areas. Abbreviations: Bel = Belgium. Bengla= Bengladesh. Bur-Fa= Burkina taso. Buru= Burundi, Can= Canada. Chι= Chili. Col = Colombia. Egy= Egypt, Guι = Guinea, Hon= Honduras, Pak= Pakistan. Rwa= Rwanda, Tun= Tunesia. Table 6 shows a comparison of LiPA results versus rifampicin resistance determination in culture for M. tuberculosis. S = Sensitive. R = Resistant. ~~> FIGURE LEGENDS Fig. 1 represents the nucleotide sequence and the amino acid sequence of the mutation region of respectively the rpoB gene and the RNA polymerase β-subunit ot a wild-type (i.e. not resistant) Mycobacterium tuberculosis strain (ITG 9081). The codon (amino acid) numbering is as in Telenti et al. ( 1993a). The nucleotides or amino acids involved in resistance-inducing changes are underlined. The observed mutations are boxed. The horizontal bars indicate the positions of some ot the ohgonucleotide probes (one probe per group is indicated). Fig 2 shows the partial nucleotide sequence ot the newly described rp_oB mutant allele ot M tuberculosis strain ITG 9003 (SEQ ID NO 34) Fig 3 shows results obtained on LiPA-stπps w ith probes S44 and S4444 applied at different concentrations on the membrane strip. As target material, nucleic acid preparations of JVL tuberculosis strains ITG 8872 and ITG 9081 were used. Fig 4 gives a comparison of the performance of probes S44 and S4444 in a Line probe assay conformation. The probes on strip A and B are identical except tor S44 and S4444 The hybridizations were performed using amplified material originating from JVL tuberculosis strain ITG 8872. Fig 5 shows the partial nucleotide sequence ot the presumptive rp_oB gene of M. paratuberculosis strain 316F (SEQ ID NO 35) Fig 6 shows the partial nucleotide sequence ot the presumptive rp_oB gene of M. avium strain ITG 5887 (SEQ ID NO 36) Fig 7 shows the partial nucleotide sequence of the presumptive rp_oB gene of M. scrotulaceum strain ITG 4979 (SEQ ID NO 37) Fig 8 shows the partial nucleotide sequence of the presumptive rp_oB gene of M- kansasn strain ITG 4987 (SEQ ID NO 56) Fig 9 shows some rpoB mutations in M. tuberculosis and their corresponding LiPA patterns. Nomenclature of the mutations is as described in Table 1. Nomenclature of the LiPA pattern is as follows: wt= positive hybridization with all S-probes. and negative hybridization with all R-probes: AS 1-5 = absence of hybridization with the respective S-probe: R2. 4A, 4B. 5 = positive hybridization with the respective R-probes and absence of hybridization with the corresponding S-probe; C = positive control line: should be positive when the test is carried out properly: Mtb= MT-POL-probe. Only one probe of each group is mentioned, but it stands for the whole group: e.g. S5 stands for S5. S55, S555, S5555, S55C, S55M. Fig. 10 shows the frequency of the different mutations encountered in the rifampicin- resistant M. tuberculosis strains analysed by LiPA. Nomenclature is as in Fig. 9. "Mix" means that a mix of strains was present in the sample. "Double" means the presence of two mutations in one strain. Fig. 1 1 shows the partial nucleotide sequence of the presumptive rp_oB gene of MAC strain ITG 926 (SEQ ID NO 69). Example 1 : Amplification of the rpoB gene fragment in M. tuberculosis After nucleic acid extraction from mycobacterial isolates (either cultured or present in body fluid or tissue) 2 μ\ product was used to amplify the relevant part of the ΓTJO B gene by using one or more combinations between the 5 ' -pπmers (P I (SEQ ID NO 30), P2, P3 (SEQ ID NO 31) and P7 (SEQ ID NO 41)) and the 3 ' -pπmers (P4 (SEQ ID NO 32). P5 (SEQ ID NO 33), P6 and P8 (SEQ ID NO 42). The sequence of these primers is given in Table 2. PI , P3. P4. P5. P7 and P8 are new primer sequences, described by the current invention. P2 and P6 have been described before (Telenti et al. 1993a). These primers may be labeled with a label of choice (e.g. biotine). Different primer- based target-amplification systems may be used. For amplification using the PCR. the conditions used are described hereafter. Single-round amplification with primers PI and P5 involved 35 cycles of 45sec/94°C, 45sec/58°C. 45sec/72°C. If a nested PCR was preferable, in the second round primers P3 and P4 were used and 25 cycles (45sec/94°C. 60sec/68°C) were performed starting from 1 μ\ of first round product. If P3 and P4 were used in a single-round PCR, the following cycling protocol was used : 30 cycles of l mιn/95°C, lmιn/55°C, lmιn/72°C. The same cycling protocol was used for set of primers P2/P6. PCRs were usually performed in a total volume of 50 μ\ containing 50mM KC1, lOmM Tπs-HCl (pH 8.3). 2.2mM MgCL. 200 μ\ each dNTP. 0.01 % gelatine and 1 U Taq polymerase. Primer concentrations ranged between 10 and 25 pmol/reaction. Since the set of primers P3/P4 yielded significantly stronger signals after hybridization than the set of primers P2/P6, the first set of primers was used for all further hybridization experiments. Set of primers P2/P6 was used for sequence analysis. Nested PCR using P2 and P6 as outer primers and P3 and P4 as inner (biotinylated) primers was only used for direct detection in clinical samples (expectorations and biopsies). The length of the amplified product, as monitored by agarose-gelelectrophoresis. is as follows : Primer set P1/P5 : 379 basepairs Primer set P3/P4 : 257 basepairs Primer set P2/P6 : 411 basepairs Primer set P7/P8 : 339 basepairs Example 2 : Sequencing of rpoB gene fragments from M. tuberculosis strains DNA extracted from mycobacterial isolates known to be resistant or sensitive to rifampicin was amplified using the set of primers P2/P6 (ot which P6 was biotinylated at the 5' end). Direct sequencing of single stranded PCR-product was performed by using streptavidin coated beads and the Taq Dye Deoxy Terminator / Cycle Sequencing kit on an ABI373A DNA sequencer (Applied Biosystems. Forster City, CA. USA) as recommended by the manufacturer. The primers used for sequencing were the same than those used for amplification (P2 or P6). As expected, all sensitive (= sensitive in culture and sensitive LiPA pattern) strains sequenced (7) yielded a wild-type sequence (no mutation). In most resistant strains a mutation could be identified. Most of these mutations have been previously described (Telenti et al.. 1993a 1993b, Kapur et al. 1994). However. 4 new mutations are described in the current invention: D516G, H526C, H526T and R529Q (see also Table 1 (")). The full sequence of the amplified rpoB fragment ot mutant allele H526C (isolate ITG 9003) is shown in Fig. 2 (SEQ ID NO 34) by way of an example. A few strains (3 80, see table 6) were resistant to rifampicin in culture but showed a wild-type LiPA pattern. After sequencing, these isolates all showed a wild-type rpoB gene sequence, confirming the hybridization results. It is therefore possible that tor these isolates a different molecular mechanism of rifampicin resistance applies Example 3 : Development of the Line Probe Assay (LiPA)-strip The principle and protocol of the line probe assay was as described earlier (Stuyver et al.. 1993) with a few exceptions. Instead of the incorporation of biotinylated dUTP, biotinylated primers were used and the hybridization and stringent wash were performed at 50°C in 3 x SSC/20% deionized formamide. The mutations in the rpoB gene leading to resistance to rifampicin are mainly located m a small area of the gene spanning 67 nucleotides (23 ammo acid codons). At least 17 nucleotides, evenly mtersperced over this region, are involved in mutations leading to at least 28 different am o acid changes. Such a complexity ot nucleotide changes poses problems for the detection of all these changes in a single hybridization step. In principle, per mutated site one wild-type probe would be needed and per nucleotide change one mutant-probe specifically detecting that particular mutation. Hence, a hybridization test would involve at least about 35 sequence specific ohgonucleotide probes which would render this test complex to manufacture and use. and consequently commercially less attractive. Therefore a particular approach was designed making use ot carefully chosen wild- type (S-) probes, each spanning more than one polymorphic site and overlapping the complete area of relevance (see fig. 1 ). Doing so. the set of at least 10 wild-type probes could be reduced to a total of five or six probes. These probes were meticulously adjusted experimentally such that the presence of each resistance causing mutation in the rpoB mutation region resulted in a clearly detectable decrease in hybrid-stability between the target and at least one ot these probes under the same hybridization and wash conditions. Since with this combination of probes all relevant mutations described so far can be detected, rifampicin resistance can be monitored in Mycobacterium tuberculosis isolates. This set of probes is also able to detect the presence of non-described mutations, e.g. the TGC mutation at position 526 in strain ITG 9003. Although strictly taken the addition of mutant (R-) probes to the selected panel of wild-type probes is obsolete, for scientific purposses it might be informative to detect the exact point mutation present. Therefore. 4 mutant probes (R2. R4A. R4B. R5) were designed which correspond to the most frequently occurring mutations and which, taken together, are able to positively identify more than 70% of all resistant cases (see fig. 10). Additional mutant probes (e.g. Rl . R2B. R2C. R3. R4C, R4D. R4E. R5B. R5C) may be added to this set of 4 in order to positively identify most clinically relevant resistant cases. The addition of these probes also adds to the reliability of the assay since the appearance of a mutant probe should inevitably result in the disappearance of a wild-type probe if one is not dealing with mixed infections. In some cases, it may be of clinical relevance to distinguish between the different mutations possibly present. This situation may occur for instance at amino-acid position 516. If at that position the normal (wild-type) amino acid present (Aspartic acid), changes into a Valine or Tyrosine, high level resistance or intermediate level resistance to rifampicin is induced; however, unpublished data seem to indicate that the sensitivity to rifabutin is maintained. Hence, for infections by strains with this mutation, rifabutin would still be effective where as rifampicin is not. The same may be true for codon 51 1 but, to our knowledge, these are the only mutation-sites for which the effect of rifampicin and rifabutin might be different: usually strains resistant to rifampicin are also resistant to rifabutin. In order to develop a LiPA-strip to detect the presence of mutations generating resistance to rifampicin (and/or rifabutin) in M. tuberculosis a total of 36 ohgonucleotide probes were synthesized and evaluated in a reverse hybridization test. The sequence of these probes is shown in Table 2A (wild-type and mutation probes). The first set of probes tested was : SI , S2. S3, S4, S5, R2. R4A, R4B and R5. Under the conditions used for reverse hybridization most probes did not perform as theoretically expected and modifications had to be introduced le^ π, g to the synthesis and evaluation of the following additional probes : S I 1. S33, S44. S4444, S5555, R44A, R444A. R44B, R444B. R55. From the total panel of probes, probes exhibiting the most optimal features with respect to specificity and sensitivity, under the same experimental conditions were selected for further use. The prefered probes with wild-type sequences (S-probes) which together overlap the entire rpoB region of interest are : S l l , S2. S33, S4444 and S55 or S5555 (see Table 2). Resistance will be detected by a loss of hybridization signal with any of these S-probes. The prefered mutation probes (R-probes) are : R2, R444A. R444B and R55 (see table 2). In some cases of resistance a loss of hybridization signal with the S-probes may be accompanied by a positive hybridization signal with the corresponding R-probe. By wav of an example, some of the rpoB-mutations and their corresponding LiPA pattern are shown in Fig. 9. Although the probes from the same group (e.g. probes S4, S44. S444 and S4444) are differing only slightly from each other, their hybridization characteristics may vary considerably. This is illustrated by way of example in an experiment in which the performance of probes S44 and S4444 is compared using PCR products originating from two JVL tuberculosis strains (ITG 8872 and ITG 9081 ) both displaying a wild-type sequence in the target region of probes S44 and S4444. The difference between both probes is shown below : S44 GGTTGACCCACAAGCGCCGA I I II I I I I I I I I I I I I I I S4444 TTGACCCACAAGCGCCGACTGTC Probe S44 was chosen on a theoretical basis from the known gene sequence (Telenti et al.. 1993a). This probe would be theoretically the best probe for discriminating mismatches in the CAC-codon (underlined) since this codon is in the central part of the probe. However, in contrast to the general rules, the performance of probe S4444 proved to be significantly better (as described in the following experiment). Both probes were applied to nitrocellulose strips in different amounts (2.4. 1.2 and 0.6 pmoi/stπp). After fixation and blocking of the strips, the probes were hybridized with biotinylated PCR fragments (from strains IGT 8872 and ITG 9081 ) as described earlier. The results are shown in Fig. 3. Under the hybridization conditions used (3 x SSC. 20% deionized formamide. 50°C) the signals obtained with probe S44 are very weak. On the other hand probe S4444 generates very strong and reliable signals. Consequently, probe S4444 is prefered over S44 for use on the LiPA-stπp. This dramatic effect cannot only be attributed to the difference in length of both probes, but also the location seems to be of importance. Most probably the secundary structure of the target region of the probes highly influences the hybridization characteristics. In Fig. 4 the results of another experiment are shown in which the performance of both probes is compared in the context of the other probes. Both strips A and B are identically processed using amplified product originating from strain ITG 8872. Both strips are almost identical except that strip A contains probe S44 (0.6 pmol) and strip B probe S4444 (0. 1 pmol) and the order of the probes applied to the strip is different. On strip A probe S44 is negative whereas on strip B probe S4444 is clearly positive, although in both cases there is a perfect match between the target and the probe and in both cases a positive result would have been expected. These results clearly illustrate that probe design, especially under the fixed conditions of the reverse hybridization format (the same conditions tor each probe) is not straightforward and probes have to be evaluated meticulously before they can be used in a reverse hybridization format. In general we can state that suitable probes cannot always be simply derived on a theoretical basis from a known gene sequence. Although not detected among the isolates tested in the current invention, the presence of a silent mutation may give rise to a resistant pattern on the strips (one wild-type probe missing) while the strain is sensitive. Up to now only one silent substitution has been described (in codon 528 : CGC → CGT; Telenti et al.. 1993a). This mutation would result in a destabi zation of the hybrid with probe S-4444. However, by adding to the strip a probe specific for the silent mutation (Probe SIL- 1. Table 2), this silent mutation can be discriminated from resistance inducing mutations and would prevent misinterpretation ot the pattern observed. Moreover, the SIL-probes can be applied on the strip at the same location than the corresponding S-probes (mixed probes). Doing so. no loss ot hybridisation signal would be observed as a result of the silent mutation. In order to detect the insertion mutations conferring rifampicin resistance. 514ιnsF and 514ιnsFM (see Fig. 1), two new wild-type probes were designed. S6 and S66, the sequence of which is represented in Table 2. Hybridization with nucleic acids originating from strains harbouring these insertion mutations, results in the absence of a hybridization signal with S6 and S66 (see also Table 1). In order to positivelv identify more mutations than those detected by the set of R2. R4A R4B and R5. a number ot additional R-probes were designed, which may be added to the LiPA strip, using the same hybridization and wash conditions. Together with the above- described R-probes, the additional R-probes (Rl . R2B, R2C. R3. R4C, R4D. R4E. R5B, R5C) allow a positive identification of the mutations most frequently encountered m the strain collection tested in the current application. Example 4 : Probe specific for the JVL tuberculosis complex A line probe assay was developed in order to enable the simultaneous detection of the mutations causing resistance to rifampicin directly coupled to detection of the pathogen in casu M. tuberculosis. Since it is extremely advantageous to be able to detect simultaneously the presence of JVL tuberculosis and the presence or absence of a gene or mutation causing drug- resistance, the aim was to develop a ____ . tuberculosis probe contained in the same PCR fragment as at least one of the relevant resistance markers to be identified. Therefore rpoB genes of non-M. tuberculosis isolates were sequenced. These organisms were : M. paratuberculosis 316F, JVL avium ITG5887, M. scrotulaceum ITG4979 and JVL kansasii ITG4987. The sequences of the corresponding IJJOB gene fragments are shown in Fig. 5 to 8. respectively. In addition, the sequence of the rp_oB gene fragments of JVL leprae and M. intracellulare were known from the literature (Honore and Cole. 1993: Guerrero et al.. 1994). Comparison of these sequences with the rpoB gene sequence of VL tuberculosis enabled the delineation of a specific region (outside the region responsible for resistance) in the rpoB gene fragment from which the development of probes, potentially specific for JVL tuberculosis appeared feasible. An ohgonucleotide probe (further referred to as MT-POL-l) derived from that region with the following sequence : GGA CGT GGA GGC GAT CAC ACC (SEQ ID NO 23) was further evaluated with respect to its sensitivity and specificity by hybridization on LiPA strips. The amplification and hybridization conditions were as described above. The results are summarized in Table 3. In addition to the four JVL tuberculosis strains listed in Table 3, 521 more JVL tuberculosis clinical isolates were tested: all isolates gave a positive hybridization signal. Evidently, also JVL . bovis strains hybridize with the probe, but it is clinically not relevant to distinguish JVL . tuberculosis from ML bovis for this purpose. In fact, throughout the application the term "JVL tuberculosis" can be replaced by "ML tuberculosis complex", referring to M- tuberculosis s.s.. JVL bovis. M. africanum and M. microti. without affecting the significance of the results. Although, using the sets of primers described in example 1. a PCR product may be obtained with DNA of some other Mycobacterium species and even some genetically unrelated micro-organisms which might also be present in the respiratory tract, none of these bacteria showed hybridization with the selected MT-POL- l probe. In conclusion we can state that the selected probe is highly specific for JVL tuberculosis complex strains and 100% sensitive for ML tuberculosis. Also other probes from this region might be useful for the speci: detection of M. tuberculosis complex strains, such as : MT-POL-2. MT-POL-3, MT- POL-4 and MT-POL-5 (see Table 2). In a similar way, the following probes can be used to differentiate JVL avium. JVL paratuberculosis. ML scrofulaceum , JVL kansasii, JVL intracellulare and JVL leprae strains from each other and from other mycobacteria : MA-POL- 1. MP-POL- 1 . MS-POL- 1 , MK- POL-1. MI-POL-1 and ML-POL-1 respectively (see table 2B). Example 5 : Evaluation of LiPA strips for M. tuberculosis LiPA strips were prepared carrying the following probes (in addition to a positive control line) : MT-POL-l . Sl l , S2, S33. S4444. S5555, R2. R444A. R444B. R55. These strips were hybridized with PCR products from M. tuberculosis strains for which the relevant rrjoB gene sequence was determined. Some representative results are summarized in Table 4. The hybridization results completely correlated with the sequencing results, indicating that the probes used can discriminate at the l . el of a single mismatch. Each mutation screened for could be detected either by the absence of one of the wild-type probes (S- probes) or by the absence of a wild-type probe together with the presence of the corresponding mutant probe (R-probe). In the latter case, the exact mutation present can be derived from the hybridization results. However, the knowledge of the exact mutation present is not necessary to determine whether or not one is dealing with a strain resistant to rifampicin since each mutation screened for confers resistance. Sensitive strains, i.e. strains without mutations in the relevant part of the rpoB gene, give positive reactions on all S- probes while all R-probes score negative ( = wt-pattern). Example 6 : Direct detection of JVL tuberculosis strains and rifampicin- resistance in clinical samples Sixty-eight clinical specimens from different geographical origins ( 13 and 35 sputum specimens from Belgium and Rwanda respectively, and 20 lymph node biopsies from Burundi) all positive in culture for L tuberculosis and kept at -20°C were analyzed. Sample preparation for amplification was based on the procedure of Boom et al. ( 1990) modified by De Beenhouwer et al. (submitted). A nested PCR approach for the relevant region of the rpoB gene was carried out with biotinylated inner primers (P3 and P4). After thermal cycling, the amplified product was incubated with the LiPA strip. Rifampicin resistance was determined on Lowenstein-Jensen using the proportion method of Canetti et al. ( 1963). For resistant strains, the MIC (Minimal Inhibitory Concentration) of rifampicin was determined on 7H 10 agar (Heifets, 1988). Microscopically. 20 (29.4%) samples were negative, 15 (22. 1 %) weakly positive ( 1 + or less according to the scale of the American Thoracic Society) and 33 (48.5 %) strongly positive ( >_ +2) upon Ziehl-Neelsen staining. The LiPA detected rifampicin sensitivity in 49 specimens (only M. tuberculosis and wild-type probes positive) and resistance in 19 specimens (JVL tuberculosis probe positive, one of the wild-type probes missing, and eventually one of the mutation probes positive). In vitro rifampicin susceptibility testing confirmed these results with three exceptions. For all the sensitive strains, a sensitive probe pattern was observed indicating that possible silent mutations were not detected in this series. All strains displaying a resistance pattern were found to be resistant by conventional techniques. For three specimens (from three multidrug resistant patients from Rwanda) a sensitive pattern was obtained by PCR-LiPA while culture revealed resistance (MIC > 2 μg/ml on 7H10). Sequencing of the rrjgB region of these strains confirmed the wild-type gene sequence, possibly implying a different mechanism of rifampicin resistance in these cases or a mutation in another part of the rpoB-gene. It is also interesting to note that the nested PCR system gave positive results for all the tested specimens positive in culture including 20 Ziehl-Neelsen negative specimens. In another experiment (data not shown) including 17 smear negative sputum specimens from clinically suspected tuberculosis cases negative in culture, no signal at all was obtained with the LiPA system, indicating that the infections were most probably not caused by ML tuberculosis. In a subsequent experiment, a large collection ot clinical specimens from different geographical origin were tested in LiPA. Results are shown in Table 5. Ot the 137 resistant strains found, quite a large number could be attributed to one of the mutations represented by the R-probes (R2, R4A. R4B, R5). Interestingly, some mutations seem to be more frequent in some countries as compared to others (e.g. in Tunesia and Egypt: R4B ( = H526D), in Rwanda: R5 (S531L)). This may eventually lead to different test formats tor different countries. On a total of 213 πfampicin-resistant strains analysed by LiPA m the current application, 151 (71 %) could be attributed to the mutations S531 L, H526D. D516V or H526Y. and were thus detectable by a positive signal with respectively probes R5. R4B, R2 and R4A (see fig. 10). On a total ot 180 strains analysed both by culture and by LiPA. correct identification (sensitive/resistant) was made in 164 ( = 91. 1 % ) of the strains (see Table 6). In three resistant strains. LiPA results and sequencing showed a wild-type rpoB-gene fragment, which indicates that the mechanism for rifampicin resistance could not be attributed to mutations in the investigated part of the rpoB gene. Thirteen of the 180 analyzed strains were resistant in LiPA but seemed to be sensitive in culture. However, after recultuπng 2 of these 13 strains in synthetic 7H 1 1 medium in stead ot the traditional Lowenstein Jensen medium, they turned out to be rifampicin resistant anyway. This uptil now unpublished finding shows that the conventional Lowenstein Jensen medium is not recommended for determination ot antibiotic susceptibility ot mycobacteria (possibly due to the presence of traces of antibiotics found in commercially available eggs used to prepare Lowenstein Jensen medium). Therefore, the percentage of discrepant strains which are resistant in LiPA but sensitive in culture (in this case 13/180 = 7.2 %) is expected to be much lower (and possibly 0%) when cultuπng is done on a synthetic medium like 7H 1 1. Interestingly, most of the rifampicin resistant isolates ( > 90%) examined in the current application were in addition resistant to isoniazid. and thus multidrug-resistant (definition of multidrug resistance = resistant to at least isoniazid and rifampicin). Rifampicin resistance can thus be considered as a potential marker tor multidrug resistance, and the above-described LiPA test may therefore be an important tool for the control of multidrug resistant tuberculosis. In conclusion, the above-described method permits correct identification of M. tuberculosis and simultaneous detection of rifampicin resistance directly in clinical specimens without preculturing. It enables easy detection of rifampicin resistance directly in a clinical specimen in less than 24 hours. Example 7 Detection of Rifampicin resistance in JVL leprae The above-described detection approach can also be applied to the detection of M leprae present in biological samples coupled to the detection ot its resistance to πtampicin. The sequence of the rpoB gene of ML leprae was described earlied by Honore and Cole ( 1993). They only identified a limited number ot mutations responsible tor rifampicin resistance in ML leprae. It can be reasonably expected that, similar to J tuberculosis, a lot ot other mutations may cause rifampicin resistance in ML leprae. and that most of these mutations will be localized in a rather restricted area ot the rrjoB gene, corresponding to the "mutation region" described earlier in this application. Therefore, a set ot wild-type probes is selected overlapping the putative mutation region in the rpoB-gene ot M leprae (see table 2B) ML-S 1 (SEQ ID NO 58) ML-S2 (SEQ ID NO 59) ML-S3 (SEQ ID NO 60) ML-S4 (SEQ ID NO 61) ML-S5 (SEQ ID NO 62) ML-S6 (SEQ ID NO 63) Rifampicin resistance is revealed by an absence ot hybridization with at least one ot these ML-S probes. This set ot ML-S probes will detect πtampicin-resistance causing mutations in this region, even though the sequence ot these mutations has not yet been specified. The above-mentioned ML-S probes have been carefully designed in such a way that they can all be used under the same hybridization and wash conditions. The same holds tor the species specific ML-POL-1 probe, with which the ML-S probes can be combined to allow a simultaneous detection ot ML leprae and its resistance to rifampicin All the probes mentioned in this example are contained in the same rrjoB gene fragment of ML leprae, which can be obtained by PCR using a set ot primers chosen from MGRPO-1 or MGRPO-2 (5' primers) and MGRPO-3 or MGRPO-4 (3 ' primers) [ ' able Table 2 : Primers and probes selected from the rpoB gene 2A: JVL tuberculosis Primers SEQ ID NO PI GAGAATTCGGTCGGCGAGCTGATCC 30 P2 TACGGTCGGCGAGCTGATCC P3 GGTCGGCATGTCGCGGATGG 31 P4 GCACGTCGCGGACCTCCAGC 32 P5 CGAAGCTTGACCCGCGCTACACC 33 P6 TACGGCGTTTCGATGAACC P7 CGGCATGTCGCGGATGGAGCG 41 P8 CGGCTCGCTGTCGGTGTACGC 42 Probes species-specific probes MT-POL-l GGACGTGGAGGCGATCACACC 23 MT-POL-2 CGATCACACCGCAGACGTTGATC 24 MT-POL-3 CATCCGGCCGGTGGTCGC 25 MT-POL-4 CTGGGGCCCGGCGGTCT 26 MT-POL-5 CGGTCTGTCACGTGAGCGTG 27 wild-tvpe probes 51 CAGCCAGCTGAGCCAATTCATG 1 S l l CAGCCAGCTGAGCCAATTCAT 2 52 TTCATGGACCAGAACAACCCGC 3 53 AACCCGCTGTCGGGGTTGA 4 S33 AACCCGCTGTCGGGGTTGACC 5 54 GTTGACCCACAAGCGCCGA 6 S44 GGTTGACCCACAAGCGCCGA 7 S444 TTGACCCACAAGCGCCGACTGT 43 S4444 TTGACCCACAAGCGCCGACTGTC 8 55 GACTGTCGGCGCTGGGG 9 S55 CGACTGTCGGCGCTGGGGC 10 S555 GACTGTCGGCGCTGGGGCC 39 S5555 GACTGTCGGCGCTGGGGC 40 S55C GCCCCAGCGCCGACAGTCG 44 S55M CGACTGTCGGCGTTGGGGC 45 56 TGAGCCAATTCATGGACCAGAA 1 1 S66 CTGAGCCAATTCATGGACCAGA 12 SIL-1 CCACAAGCGTCGACTGTCG 13 mutant probes R2 AATTCATGGTCCAGAACAACCCG 14 R4A GGTTGACCTACAAGCGCCGA 15 R44A GGGTTGACCTACAAGCGCCGA 16 R444A TTGACCTACAAGCGCCGACTGTC 17 R4B GTTGACCGACAAGCGCCGA 18 R44B GGTTGACCGACAAGCGCCGA 19 R444B TTGACCGACAAGCGCCGACTGTC 20 R5 CGACTGTTGGCGCTGGGG 21 R55 CGACTGTTGGCGCTGGGGC 22 Rl CAGCCAGCCGAGCCAATTCAT 46 R2B AATTCATGTACCAGAACAACCCG 47 R2C ATGGACCAGAACCCGCTGTCG 48 R3 AACCCGCTGTTGGGGTTGACC 49 R4C TTGACCCGCAAGCGCCGACTGTC 50 R4D TTGACCCCCAAGCGCCGACTGTC 51 R4E TTGACCTGCAAGCGCCGACTGTC 52 R5B CGACTGTGGGCGCTGGGGC 53 R5C ACTGTGGGCGCCGGGGCCC 54 2B: other mycobacterial species primers MGRPO-1 CCAAAACCAGATCCGGGTCGG 64 MGRPO-2 GTCCGGGAGCGGATGACCAC 65 MGRPO-3 GGGTGCACGTCGCGGACCTC 66 MGRPO-4 GGGCACATCCGGCCGTAGTG 67 probes MP-POL-1 CATCCGTCCCGTCGTGGC 28 MA-POL- 1 CATCCGTCCAGTCGTGGCG 29 MS-POL- 1 GCCGGTCGTGGCCGCG 38 MK-POL- 1 AGCGCCGGCTTTCGGCGC 55 ML-POL- 1 GACGCTGATCAATATCCGTCCGG 57 MI-POL-1 ATCCGGCCGGTCGTCGCC 68 ML-S 1 CAGCCAGCTGTCGCAGTTCATG 58 ML-S2 GTTCATGGATCAGAACAACCCTC 59 ML-S3 AACCCTCTGTCGGGCCTGACC 60 ML-S4 ACCCACAAGCGCCGGCTGTC 61 ML-S5 GGCTGTCGGCGCTGGGC 62 ML-S6 CTGTCGCAGTTCATGGATCAGA 63 Table 3 : Hybridization results obtained with probe MT-POL- Table 4: Interpretation of LiPΛ-results for rifampicin resistance detection in JVL tuberculosis Table 5: Occurrence of different mutations in IVL tuberculosis strains originating from different countries Table 6 : Comparison of LiPA results versus rifampicin resistance determination in culture for M. tuberculosis. REFE RENCES Asseline J, Delarue M. Lancelot G. Toulme F. Thuong N ( 1984) Nucleic acid- bindir ;olecules with high affinity and base sequence specificity : intercalating agents covale linked to oligodeoxynucleotides. Proc. Natl. Acad. Sci. USA 81 ( 1 1):3297-301. Banerjee A. , Dubnau E.. Quernard A. , et al. inhA. a gene encoding a target for Isoniazid and Ethionamide in Mycobacterium tuberculosis. Science 1994: 263: 227-30. Barany F. Genetic disease detection and DNA amplification using cloned thermostable ligase. Proc Natl Acad Sci USA 1991 : 88: 189-193. Bej A, Mahbubani M. Miller R. Di Cesare J. Haff L. Atlas R. Mutiplex PCR amplification and immobilized capture probes for detection of bacterial pathogens and indicators in water. Mol Cell Probes 1990: 4:353-365. B >om R. , Sol C.J.A. , Salimans M.M.M.. et al. Rapid and simple method for purification of nucleic acids. J Clin Microbiol 1990: 28: 495-503. Canetti G.. Fro an S. , Grosset J.. et al. Mycobacteria : laboratory methods for testing drug sensivity and resistance. Bull WHO 1963: 29: 565-79. Claridge J.E.. Shawar R.M. , Shinnick T.M. and Pi kaytis B.B. Large-scale use of polymerase schain reaction for detection of Mycobacterium tuberculosis in a routine mycobacteriology laboratory. J Clin Microbiol 1993; 31 : 2049-56. Compton J. Nucleic acid sequence-based amplification. Nature 1991 : 350: 91-92. Culliton B. Drug resistant Tb may bring epidemic. Nature 1992: 356 : 473. Douglas J.. Steyn L.M. A ribosomal gene mutation in streptomycin-resistant Mycobacterium tuberculosis isolates. J. Infect. Dis. 1993; 167 : 1505-1506. Duck P. Probe amplifier system based on chimeπc cycling oligonucleotides. Biotechmques 1990; 9: 142-147. Finken M. , Kirschner P. , Meier A.. Wrede A. , and Bottger E. Molecular basis of streptomycin resistance in Mycobacterium tuberculosis: Alternations ot the ribosomal protein S 12 gene and point mutations within a functional 16S ribosomal RNA pseudoknot. Mol Microbiol 1993: 9: 1239-46. Guatel J, Whitfield K. Kwoh D. Barrmger K. Richman D. Gengeras T. Isothermal, in vitro amplification of nucleic acids by a multienzyme reaction modeled after retroviral replication. Proc Natl Acad Sci USA 1990: 87: 1874- 1878 Guerrero et al. Evaluation ot the rpoB gene in rifampicin susceptible and resistant M. avium and M. intracellulare. J. Antimicrob. Chemotherapy 1994: 33: 661-663. Heifets L. Qualitative and quantitative drug-susceptibility tests in mycobacteπology. Pulmonary perspective. Am Rev Respir Dis 1988; 137: 1217- 1222. Honore N. and Cole S. Molecular basis of rifampicin resistance in M leprae. Antimicrobial Agents and Chemotherapy 1993: 37: 414-418. Kapur V. , Li L.. Iordanescu S. et al. Characterization by automated DNA sequencing of mutations in the gene (rpoB) encoding the RNA polymerase β subunit in rifampicin resistant Mycobacterium tuberculosis strains from New York City and Texas. J. Clin. Microbiol. 1994: 32: 1095- 1098. Kwoh D. Davis G. Whitfield K. Chappelle H. Dimichele L. Gingeras T. Transcription-based amplification system and detection ot amplified human immunodeficiency virus type 1 with a bead-based sandwich hybridization format. Proc Natl Acad Sci USA 1989: 86: 1 173-1 177. Kwok S. Kellogg D. McKinney N. Spasic D. Goda L. Levenson C. Smisky J. Effects of primer-template mismatches on the polymerase chain reaction- Human immunodeficiency views type 1 model studies. Nucl. Acids Res. 1990; 18: 999 Landgren U, Kaiser R. Sanders J. Hood L. A hgase-mediated gene detection technique. Science 1988: 241: 1077-1080. 5 Lomeh H, Tyagi S. Pπntchard C. Lisardi P. Kramer F. Quantitative assays based on the use ot rep catable hybridization probes. Clin Chem 1989: 35. 1826- 1831. Matsukura M. Shinozuka K, Zon G. Mitsuya H. Reitz M, Cohen J. Broder S (1987) Phosphorothioate analogs ot o godeoxynucleotides : inhibitors ot replication and cytopathic effects ot human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 84(21 ):7706-10. 10 Middlebrook G. (1954a). Isoniazid-resistance and catalase ity or tubercle bacilli. Am. Rev. Tuberc , 69 : 471-472. Middlebrook G. , Cohn M.L. , Schaefer W.B. ( 1954b) Studies on isoniazid and tubercle bacilli. III. The isolation, drug-susceptibility, and catalase-testing ot tubercle bacilli from isoniazid-treated patients. Am. Rev. Tuberc , 70 : 852-872. 15 Miller P. Yano J. Yano E. Carroll C. Jayaram K. Ts ' o P ( 1979) No onic nucleic acid analogues. Synthesis and characterization of dideoxyπbonucleoside methylphosphonates. Biochemistry 18(23):5134-43. Nair J. Rouse D A, Bai G H. Morris S L. The rp_sL gene and streptomycine resistance in single and multiple drug-resistant strains or Mycobacterium tuberculosis. Mol. '.0 Microbiol. 1993: 10 : 521-527. Nielsen P. Egholm M, Berg R, Buchardt O (1991) Sequence-selective recognition ot DNA by strand displacement with a thymine-substituted polyamide. Science 254(5037): 1497- 500. Nielsen P, Egholm M. Berg R. Buchardt O ( 1993) Sequence specific inhibition ot DNA restriction enzyme cleavage by PNA. Nucleic-Acids-Res. 21 (2). 197-200 Saiki R, Walsh P, Levenson C. Erlich H. Genetic analysis ot amplified DNA with immobilized sequence-specific ohgonucleotide probes Proc Natl Acad Sci USA 1989; 86:6230-6234. Stoeckle M Y, Guan L. Riegler N et al. Catalase-peroxidase gene sequences in Isoniazid-sensitive and -resistant strains of Mycobacterium tuberculosis from New York City. J. Inf. Dis. 1993; 168 : 1063-65. Stuyver L. Rossau R. Wyseur A. et al. Typing ot hepatitis C \ irus isolates and characterization of new subtypes using a line probe assay. J. Gen. Virol. 1993; 74 : 1093- 1 102. Telenti A. , Imboden P. , Marches I F.. et al. Detection ot πtampicin-resistance mutations in Mycobacterium tuberculosis Lancet 1993a; 341 : 647-50. Telenti A. , Imboden P.. Marchesi F.. et al. Direct, automated detection of Rifampin- resistant Mycobacterium tuberculosis by polymerase chain reaction and single-strand conformation polymophism analysis. Antimicrob Agents Chemother 1993b 37. 2054-58. Wu D, Wallace B. The ligation amplification reaction (LAR) - amplification of specific DNA sequences using sequential rounds of template-dependent ligation. Genomics 1989: 4:560-569. Youatt J. ( 1969). A review of the action of isoniazid. Am. Rev. Respir. Dis.. 99 : 729-749. Zhang Y. , Heym B.. Allen B. , Young D. and Cole S. The catalase-peroxidase gene and isoniazid resistance of Mycobacterium tuberculosis. Nature 1992: 358: 591-93.

Claims: CLAIMS 1. Method for the detection of the antibiotic resistance spectrum of Mycobacterium species present in a sample, possibly coupled to the identification of the Mycobacterium species involved, comprising the steps of : (i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (ii) if need be amplifying the relevant part of the antibiotic resistance genes present in said sample with at least one suitable primer pair as described in claims 22 to 24; (iii) hybridizing the polynucleic acids of step (i) or (ii) with at least one of the rpoB gene probes, as specified in table 2, under appropiate hybridization and wash conditions; (iv) detecting the hybrids formed in step (iii): (v) inferring the Mycobacterium antibiotic resistance spectrum, and possibly the Mycobacterium species involved, from the differential hybridization signal(s) obtained in step (iv). 2. Method according to claim 1 for detection of rifampicin (and/or rifabutin) resistance of JVL tuberculosis present in a biological sample, comprising the steps of: (i) if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (ii) if need be amplifying the relevant part of the rpoB gene with at least one suitable primer pair as described in claims 22 to 23; (iii) hybridizing the polynucleic acids of step (i) or (ii) with a set of probes, under appropiate hybridization and wash conditions, with said set comprising at least one of the following rpoB wild-type or S-probes as specified in Table 2: S444 (SEQ ID NO 43). S4444 (SEQ ID NO 8), 55 (SEQ ID NO 9), S55 (SEQ ID NO 10), S555 (SEQ ID NO 39), S5555 (SEQ ID NO 40). S55C (SEQ ID NO 44), S55M (SEQ ID NO 45), 56 (SEQ ID NO 1 1). and/or. S66 (SEQ ID NO 12). ( iv) detecting the hybrids formed in step ( in) ■ (\ ) inferring the rifampicin susceptibility (sensitn ity versus resistance) ot M. tuberculosis present in the sample from the differential hybridization sιgnal(s) obtained in step (iv). 3. Method according to claim 2. wherein step (in) consists ot hybridizing with a set of probes comprising at least 5 or 6 of the specified S-probes ot claim 2. wherein said probes taken together cover the mutation region ot the rp_p_B gene. 4. Method according to claims 2 or 3. wherein step (in) consists ot hybridizing with a set ot probes comprising at least one and preferably all ot the following set ot S-probes as specified in Table 2: S l l (SEQ ID NO 2), S2 (SEQ ID NO 3). S33 (SEQ ID NO 5). S4444 (SEQ ID NO 8). and/or. S55 or S5555 (SEQ ID NO 10 or 40). 5 Method according to any of claims 2 to 4. wherein step (in) consists of hybridizing with a set of probes as defined in any of claims 2 to 4. further comprising at least one rpoB silent mutation probe as specified in Table 2. such as: SIL-1 (SEQ ID NO 13). 6. Method according to any of claims 2 to 5. wherein step (iii) consists of hybridizing with a set of probes as defined in any of claims 2 to 5. with said set further comprising at least one rpoB mutation or R-probe. with said probe being selected from the following list of R-probes as specified in Table 2: 7. Method according to claim 6, wherein step (iii) consists of hybridizing with a set cf probes, with said set comprising at least one of the following R-probes as specified in ~~ Xle 2; R2 (SEQ ID NO 14), R444A (SEQ ID NO 17), R444B (SEQ ID NO 20). and/or. R55 (SEQ ID NO 22). 8. Method according to claim 2, wherein step (in) consists ot hybridizing with a set ot probes, with said set comprising at least the following S-probes as specified in Table 2: S4444 (SEQ ID NO 8). and. S55 (or S5555) (SEQ ID NO 10 or 40) 9. Method according to claim 2. wherein step (in) consists ot hybridizing to a set of probes with said set comprising at least the following S-probes as specified in Table 2: S2 (SEQ ID NO 3). S4444 (SEQ ID NO 8). and. S55 (or S5555) (SEQ ID NO 10 or 40) 10. Method according to any of claims 8 or 9. wherein step (in) consists of hybridizing to a set of probes, w ith said set further comprising at least one R-probe chosen from the follow ing list of R-probes as specified in Table 2- R2 (SEQ ID NO 14), R444A (SEQ ID NO 17), R444B (SEQ ID NO 20), and/or. R55 (SEQ ID NO 22). 1 1. Method according to any of claims 2 to 10 tor the simultaneous identification ot Mycobacterium tuberculosis present in a sample and the detection ot its rifampicin (and/or rifabutin) resistance, wherein step (in) consist of hybridizing to set ot probes further comprising at least one probe specific for Mycobacterium tuberculosis, with said probe being preferentially contained in the amplified rpoB gene fragment, and with said probe being preferentially chosen from the following group of probes as specified in Table 2: MT-POL-l (SEQ ID NO 23), MT-POL-2 (SEQ ID NO 24), MT-POL-3 (SEQ ID NO 25), MT-POL-4 (SEQ ID NO 26), and/or. MT-POL-5 (SEQ ID NO 27). 12. Method according to claim 1 1. wherein step (in) consist ot hybridizing to a set of probes comprising the following probe as specified in Table 2. MT-POL-l (SEQ ID NO 23). 13. Method according to any of claims 1 1 to 12 for the simultaneous identification of M- tuberculosis and mycobacteria other than JVL tuberculosis, coupled to detection of rifampicin resistance of JVL tuberculosis, wherein step (in) consists ot hybridizing with a set of probes further comprising at least one of the following species-specific probes as specified in Table 2- MP-POL- 1 (SEQ ID NO 28), MA-POL- 1 (SEQ ID NO 29), MS-POL-1 (SEQ ID NO 38), MK-POL-1 (SEQ ID NO 55), MI-POL- 1 (SEQ ID NO 68). and/or. ML-POL-1 (SEQ ID NO 57), and/or any M. paratuberculosis specific probe derived from the sequence of the relevant part of the rpoB gene of M. paratuberculosis (SEQ ID NO 35). and/or any M. avium specific probe derived from the sequence of the relevant part of the rpoB gene of M. avium (SEQ ID NO 36). and/or any M. scrofulaceum specific probe derived from the sequence of the relevant part of the rpoB gene of M. scrofulaceum (SEQ ID NO 37). and/or any M. kansasii specific probe derived from the sequence ot the relevant part of the rpoB gene of M. kansasii (SEQ ID NO 56). and/or any MAC-strain specific probe derived from the sequence of the relevant part of the rpoB gene ot a MAC-strain (SEQ ID NO 69). 14. Method according to claim 12, wherein step (in) consists ot hybridizing with the following set of probes as specified in Table 2: MT-POL-l (SEQ ID NO 23), 15. Method according to any of claims 2 to 14 for the detection ot rifampicin (and/or rifabutin) resistant Mycobacterium tuberculosis present in a sample using a probe or a set of primers designed to specifically detect or amplify the new rp_oB gene mutations D516G, H526C. H526T and R529Q. 16. Method according to claim 1 for the detection of rifampicin (and/or rifabutin) resistance of JVL leprae present in a biological sample, comprising the steps ot: (0 if need be releasing, isolating or concentrating the polynucleic acids present in the sample; (u) if need be amplifying the relevant part of the rpoB gene with at least one suitable primer pair as described in claim 24; (in) hybridizing the polynucleic acids of step (I) or (n) with a selected set of rpoB wild- type probes under appropiate hybridization and wash conditions, with said set comprising at least one of the following probes as specified in Table 2: ML-S 1 (SEQ ID NO 58). ML-S2 (SEQ ID NO 59). ML-S3 (SEQ ID NO 60). ML-S4 (SEQ ID NO 61), ML-S5 (SEQ ID NO 62). or, ML-S6 (SEQ ID NO 63). (iv) detecting the hybrids formed in step (in), (v) inferring the rifampicin susceptibility (sensitivity versus resistance) of JVL leprae present in the sample from the differential hybridization sιgnal(s) obtained in step (iv). 17. Method according to claim 16 for the simultaneous identification ot M leprae and detection of rifampicin resistance of M. leprae, wherein step (in) consists ot hybridizing with a set of probes further comprising the following probe as specified in Table 2: ML-POL-1 (SEQ ID NO 57). 18. Reversed phase hybridization method comprising any ot the probes as defined in any of claims 1 to 17, wherein said ohgonucleotide probes are immobilized on a solid support. 19. Reversed phase hybridization method according to claim 18. wherein said ohgonucleotide probes are immobilized on a membrane strip. 20. Probe as defined in any of claims 1 to 17 21. Composition comprising any of the probes as defined in claims 1 to 17. 22. Set of primers allowing amplification of the rpoB gene fragment of M. tuberculosis, selected from the following sets of primers as specified in Table 2: PI and P5 (SEQ ID NO 30 and 33), P3 and P4 (SEQ ID NO 31 and 32), P7 and P8 (SEQ ID NO 41 and 42), or. P2 and P6, in combination with (PI and P5) or (P3 and P4) or (P7 and P8). 23. Set of primers according to claim 22. wherein said primers are the following primers as specified in Table 2: P3 and P4 (SEQ ID NO 31 and 32). 24. Set of primers allowing the amplification of the rpoB gene fragment in mycobacteria other than JVL tuberculosis, composed of a 5' primer selected from MGRPO-1 (SEQ ID NO 64), or, MGRPO-2 (SEQ ID NO 65), and a 3'-primer, selected from: MGRPO-3 (SEQ ID NO 66), or, MGRPO-4 (SEQ ID NO 67). 25. A kit for inferring the antibiotic resistance spectrum of mycobacteria present in a biological sample, possibly coupled to the identification of the mycobacterial species involved, comprising the following components: (i) when appropiate, a means for releasing, isolating or concentrating the polynucleic acids present in the sample; (ii) when appropriate, at least one of the sets of primers according to any of claims 22 to 24: (iii) at least one of the probes as defined in any of claims 1 to 17. possibly fixed to a solid support; (iv) a hybridization buffer, or components necessary for producing said buffer: (v) a wash solution, or components necessary for producing said solution; (vi) when appropriate, a means for detecting the hybrids resulting from the preceding hybridization. 26. Kit according to claim 24 for the simultaneous detection of JVL tuberculosis and its resistance to rifampicin. wherein the sets of primers of step (ii) are as defined in claim 22 to 23. and the probes of step (iii) are as defined in any of claims 2 to 15. 27. Kit according to claim 24, for the simultaneous detection of JVL leprae and its resistance to rifampicin, wherein the sets of primers of step (ii) are as defined in claim 24, and the probes of step (iii) are as defined in claims 16 to 17.

Inventors: DE BEENHOUWER HANS, JANNES GEERT, MACHTELINCKX LIEVE, PORTAELS FRANCOISE, ROSSAU RUDI, DE BEENHOUWER, HANS, JANNES, GEERT, MACHTELINCKX, LIEVE, PORTAELS, FRANCOISE, ROSSAU, RUDI
Applicants: BEENHOUWER HANS DE, INNOGENETICS NV, JANNES GEERT, MACHTELINCKX LIEVE, PORTAELS FRANCOISE, ROSSAU RUDI, DE BEENHOUWER, HANS, INNOGENETICS N.V., JANNES, GEERT, MACHTELINCKX, LIEVE, PORTAELS, FRANCOISE, ROSSAU, RUDI
Application year: 1995
Main classification: C12Q1
IPC codes: C07H21, C12N15, C12Q1, C12R1